LB Pharmaceuticals
PublicLB Pharmaceuticals is now publicly traded
The data on this page reflects LB Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 10, 2025
Last Round
Series C
Jan 24, 2024
Total Funding Raised
$378.9M
Company Overview
LB Pharmaceuticals is a biotechnology company focused on developing innovative treatments for schizophrenia, utilizing a pro-drug approach to enhance the efficacy and safety of amisulpride for improved patient outcomes.
Sector
Biotech
AI Layer
Non-AI
Keywords
schizophrenia treatmentLB-102clinical-stage biotechneuropsychiatric therapiesCNS therapeuticssmall molecule drugantipsychotic drugbenzamide antipsychoticdopamine D2 antagonistserotonin 5-HT7 antagonistnew chemical entityNCElate-stage clinical triallong-acting injectableLAImajor depressive disorderMDDbiotech IPO
LB Pharmaceuticals Comparables
Compare LB Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eumentis Therapeutics Inc. | 70% | |
| Kynexis Therapeutics | 66% | |
| Noema Pharma | 65% | |
LB Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Sep 10, 2025 | ||||
| Series C | Jan 24, 2024 | ||||
| Series B | Sep 25, 2020 | ||||
| Series A | Mar 4, 2019 | ||||
| Seed | Apr 1, 2017 |
LB Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| TCG Crossover | Series C |
| Guggenheim Securities | IPO |
| Pontifax Venture Capital | IPO |
| Vida Ventures | IPO, Series C |
| Deep Track Capital | IPO, Series C |
| TCG Crossover | IPO |
LB Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersNew York City, New York
Employee Range49
Year Founded2015
Last FundingJan 24, 2024